Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;9(9):3234-3243.
doi: 10.1002/cam4.2811. Epub 2020 Mar 10.

Machine Learning techniques in breast cancer prognosis prediction: A primary evaluation

Affiliations

Machine Learning techniques in breast cancer prognosis prediction: A primary evaluation

Carlo Boeri et al. Cancer Med. 2020 May.

Abstract

More than 750 000 women in Italy are surviving a diagnosis of breast cancer. A large body of literature tells us which characteristics impact the most on their prognosis. However, the prediction of each disease course and then the establishment of a therapeutic plan and follow-up tailored to the patient is still very complicated. In order to address this issue, a multidisciplinary approach has become widely accepted, while the Multigene Signature Panels and the Nottingham Prognostic Index are still discussed options. The current technological resources permit to gather many data for each patient. Machine Learning (ML) allows us to draw on these data, to discover their mutual relations and to esteem the prognosis for the new instances. This study provides a primary evaluation of the application of ML to predict breast cancer prognosis. We analyzed 1021 patients who underwent surgery for breast cancer in our Institute and we included 610 of them. Three outcomes were chosen: cancer recurrence (both loco-regional and systemic) and death from the disease within 32 months. We developed two types of ML models for every outcome (Artificial Neural Network and Support Vector Machine). Each ML algorithm was tested in accuracy (=95.29%-96.86%), sensitivity (=0.35-0.64), specificity (=0.97-0.99), and AUC (=0.804-0.916). These models might become an additional resource to evaluate the prognosis of breast cancer patients in our daily clinical practice. Before that, we should increase their sensitivity, according to literature, by considering a wider population sample with a longer period of follow-up. However, specificity, accuracy, minimal additional costs, and reproducibility are already encouraging.

Keywords: Artificial Neural Network (ANN); Support Vector Machine (SVM); algorithm; breast cancer; predictive models.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Cases of recurrence and death from breast cancer in 100 mo
Figure 2
Figure 2
Length of the follow‐up
Figure 3
Figure 3
ROC curves for loco‐regional recurrence. Blue line = SVM; Red line = Artificial Neural Network Source: SPSS Modeler.
Figure 4
Figure 4
ROC curves for systemic recurrence. Blue line = SVM; red line = Artificial Neural Network Source: SPSS Modeler.
Figure 5
Figure 5
ROC curves for death from breast cancer. Blue line = SVM; red line = Artificial Neural Network Source: SPSS Modeler.

Similar articles

Cited by

References

    1. Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology. 9th ed, chapter 18. Amsterdam, Netherlands: Elsevier/Saunders; 2013;681‐714.
    1. AIOM, Airtum, Fondazione AIOM . I Numeri Del Cancro in Italia 2017. 2017.
    1. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124(7):966‐978. - PubMed
    1. Zeichner SB, Herna S, Mani A, et al. Survival of patients with de‐novo metastatic breast cancer: analysis of data from a large breast cancer‐specific private practice, a university‐based cancer center and review of the literature. Breast Cancer Res Treat. 2015;153(3):617‐624. - PubMed
    1. Yamauchi H, Woodward WA, Valero V, et al. Inflammatory breast cancer: what we know and what we need to learn. Oncologist. 2012;17(7):891‐899. - PMC - PubMed